Please note: The information displayed on this page might be outdated.
Chronos Therapeutics : Chronos Therapeutics Ltd. is a privately held UK biotechnology company focused on behavioural and degenerative diseases of the brain.
Chronos has a balanced portfolio of pre-IND programmes in addiction (orexin-1 antagonist, initially in binge eating disorder with utility in alcohol use disorder, anxiety and other compulsive disorders), fatigue (atypical dopamine active transporter inhibitor initially in MS fatigue but with utility in other central fatigue disorders) and a re-purposed asset in ALS. The company has a fourth programme targeting TrkB at the target validation stage, potential utilities include neurodegeneration and PTSD. Dr Huw Jones, CEO will present the company's portfolio and would welcome meetings with investors. Chronos currently has a single class of share with no preference arrangements or debt.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Disease Space
Central Nervous System
Industry
Biotechnology
Listing
Private
Website:
Address:
The Madgalen Centre
Oxford
Oxford, Oxfordshire Oxford, OX4 4GA
United Kingdom

Company Participants at European Biotech Investor Day 2019

  • Huw Jones, Chief Executive Officer

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.